Stockscreener 앱 받기
80.14
2.73%
-2.25
전일 마감가:
$82.39
열려 있는:
$82.48
하루 거래량:
462.92K
Relative Volume:
0.52
시가총액:
$5.20B
수익:
$569.61M
순이익/손실:
$-23.36M
주가수익비율:
-5.8908
EPS:
-13.6043
순현금흐름:
$54.87M
1주 성능:
-6.82%
1개월 성능:
-17.70%
6개월 성능:
-16.40%
1년 성능:
+7.69%
1일 변동 폭
$79.64
$82.48
1주일 범위
$78.35
$88.31
52주 변동 폭
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
80.14 | 5.20B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-02 | 개시 | Citigroup | Buy |
| 2026-05-19 | 개시 | Wolfe Research | Outperform |
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Form 4 Mirum Pharmaceuticals Inc: Robert Paul Myers (Chief Medical Officer) For: 9 October By Investing.com - Investing.com South Africa
Medical chief receives 40,000 options and a 25,000-share stock grant at Mirum Pharmaceuticals (MIRM). - Stock Titan
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
Mirum Pharmaceuticals, Inc.common stock (Nasdaq:MIRM) Stock Quote - FinancialContent
Form 4 Mirum Pharmaceuticals Inc For: 6 October By Investing.com - Investing.com Nigeria
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - stocktitan.net
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - stocktitan.net
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com UK
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - Investing.com
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Canada
Mirum CEO Christopher Peetz sells $2.96 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - stocktitan.net
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - stocktitan.net
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - stocktitan.net
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing - Yahoo Finance
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mirum Pharmaceuticals Inc 주식 (MIRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Sep 14 '26 |
Sale |
98.37 |
9,943 |
978,093 |
44,745 |
| ERIC BJERKHOLT | Officer |
Sep 14 '26 |
Proposed Sale |
98.37 |
9,943 |
978,093 |
0 |
| JOLANDA MARIE HOWE | Officer |
Sep 02 '26 |
Proposed Sale |
100.00 |
658 |
65,800 |
0 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Sep 02 '26 |
Sale |
100.00 |
658 |
65,800 |
616 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Sale |
98.68 |
30,000 |
2,960,401 |
194,440 |
| CHRISTOPHER PEETZ | Officer |
Sep 01 '26 |
Proposed Sale |
98.68 |
30,000 |
2,960,319 |
0 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Option Exercise |
2.94 |
30,000 |
88,080 |
224,440 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Aug 18 '26 |
Sale |
100.00 |
40,000 |
4,000,000 |
1,274 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Aug 18 '26 |
Option Exercise |
6.27 |
40,000 |
250,800 |
41,274 |
| JOLANDA MARIE HOWE | Officer |
Aug 18 '26 |
Proposed Sale |
100.00 |
40,000 |
4,000,000 |
0 |
0.03%
3.25%
자본화:
|
볼륨(24시간):